Pergunte a um especialista

Dr. Yu Weimiao obtained his Ph.D. from the National University of Singapore (NUS) in 2007, majoring in image processing and machine vision. He joined the Agency of Science, Technology and Research (A*STAR) in 2007. He is currently heading Computational Digital Pathology Lab (CMPL) in BII to deepen and extend the R&D with clinical and industrial partners. He is also the joint PI in IMCB leading the Computational & Molecular Pathology Lab (CMPL). His research interests are Computational Biomedical Image Analysis and Quantitative Imaging Informatics. He applied 3D image analysis solution to segment and tracking the cells in 3D to understand the developmental problem and collective cell migration mechanisms. His work was published in Nature Communication, Current biology, Nature Cell Biology, etc. To enhance the applications in clinical diagnosis/prognosis, he co-founded a biotech company, known as A!maginostic Pte. Ltd. He established a world-class joint platform for the immunodiagnosis at the tissue level. The platform allows the researchers, clinicians, and pharma to profile the patient immune signature for diagnosis, prognosis, and drug response study.